Elizabeth Gibbs
banner
gibbsem.bsky.social
Elizabeth Gibbs
@gibbsem.bsky.social
Neuroscientist in the cell/gene therapy world. Working on gene editing for neuromuscular disorders. Keen reader, tea drinker. Bluesky-curious.
Reposted by Elizabeth Gibbs
The research enterprise is invaluable. We can easily see its importance in the cures or technologies available today. But sometimes it's difficult to see what research brings to people in the shorter term. Here is one of our participants talking about what it's meant to her. youtu.be/Yn9ywYj3UYQ
SKERI • Iris Thanking Eye-Head Movement Lab (Subtitled Version)
YouTube video by The Smith-Kettlewell Eye Research Institute
youtu.be
April 28, 2025 at 6:25 PM
Reposted by Elizabeth Gibbs
Published 25 years ago, “Effective targeted gene ‘knockdown’ in zebrafish” by Nasevicius & Ekker is the 2nd most-cited #zebrafish paper (www.nature.com/articles/ng1...). They describe use of antisense morpholino-modified oligonucelotides or #morpholinos that inhibit translation. #ZebrafishFunFacts 🧪
April 4, 2025 at 4:06 PM
Reposted by Elizabeth Gibbs
Director of the Nat'l Institute of Child Health and Human Development (NICHD) was summarily dismissed yesterday. So here's your reminder that birth defects kill twice as many American kids as cancer. But there is no St. Jude's for birth defects. Only the NICHD.

www.nature.com/articles/d41...
‘One of the darkest days’: NIH purges agency leadership amid mass layoffs
In shock move, four institute directors at the US biomedical agency are removed from their posts.
www.nature.com
April 2, 2025 at 3:38 PM
Reposted by Elizabeth Gibbs
'Polls show that they think that 1/4 of our spending goes to foreign aid. In fact, on a budget for our global health work that is less than half the budget of the hospital where I did surgery here in Boston, we reached hundreds of millions of people, with programs that saved lives by the millions'
Hundreds of Thousands Will Die
The writer, surgeon, and former U.S.A.I.D. senior official Atul Gawande on the Trump Administration’s decimation of foreign aid and the consequences around the world.
www.newyorker.com
March 18, 2025 at 4:23 PM
Reposted by Elizabeth Gibbs
For #RareDiseaseDay, we’re highlighting the scientists dedicated to advancing research for rare diseases — from Duchenne muscular dystrophy to KAT6A Syndrome. Meet a few of the UCLA researchers working to understand these conditions, develop new treatments and transform patient care. 🧬
February 28, 2025 at 5:08 PM
Reposted by Elizabeth Gibbs
Over on LinkedIn, the head of the Executive Secretariat of the NIH -- a central part of NIH leadership 🧪🩺-- resigned with a lettter worth reading

www.linkedin.com/posts/nathan...
February 20, 2025 at 6:43 PM
Reposted by Elizabeth Gibbs
Duchenne gene therapy from Solid Biosciences $SLDB produces promising results in early study www.statnews.com/2025/02/18/s... via @jasonmast.bsky.social $RGRX $SRPT
Duchenne gene therapy from Solid Biosciences produces promising results in early study
Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an early sign of promise
www.statnews.com
February 18, 2025 at 1:37 PM
Reposted by Elizabeth Gibbs
Austin Leclaire played a pivotal role in spurring the development of the first medicines to treat the condition
Remembering a remarkable Duchenne champion
Patient advocate Austin Leclaire, who died Feb. 1, played a pivotal role in spurring the development of the first medicines to treat Duchenne muscular dystrophy.
buff.ly
February 6, 2025 at 8:31 PM
Reposted by Elizabeth Gibbs
Yes, they can hallucinate papers that don't exist, discuss results that seem to be imaginary, and can be confusing and inconsistent. But talking to tenured professors may still be helpful
January 14, 2025 at 10:30 PM
Reposted by Elizabeth Gibbs
Since UCLA decided to keep campus open, I’m here ready to my morning lecture class. But this is what campus looks like…
January 8, 2025 at 4:28 PM
Reposted by Elizabeth Gibbs
Do not go gently into that zoom meeting
January 2, 2025 at 8:12 PM